Prominent SLE features seen at the time of the first (baseline) and second (after five year follow up) evaluations in 78 patients enrolled in the study
| SLE features | Baseline No (%) | 5 Year follow up No (%) |
|---|---|---|
| CNS, central nervous system; anti-dsDNA, anti-double stranded DNA antibody; anti-aCL, anticardiolipin antibody; LA, lupus anticoagulant; ECLAM, European Consensus Lupus Activity Measurement score; SLICC DI, Systemic Lupus International Collaborating Clinics damage index. | ||
| Arthritis | 9 (12) | 6 (8) |
| Skin rash | 12 (15) | 10 (13) |
| Serositis | 2 (3) | 1 (1) |
| Haematol. involvement | 37 (47) | 31 (40) |
| Renal involvement | 16 (21) | 8 (10) |
| CNS involvement | 3 (4) | 2 (3) |
| Anti-dsDNA | 37 (47) | 35 (45) |
| Anti-Sm | 8 (10) | 3 (4) |
| Anti-U1RNP | 10 (13) | 9 (12) |
| Anti-SSA | 27 (35) | 22 (28) |
| Anti-SSB | 3 (4) | 5 (6) |
| Anti-aCL IgG | 42 (54) | 33 (42) |
| Anti-aCL IgM | 12 (15) | 17 (22) |
| LA | 9 (12) | 13 (17) |
| ECLAM score >2 | 43 (55) | 34 (44) |
| SLICC DI ⩾1 | 8 (10) | 14 (18) |